Abstract
This review focuses on two synthetic compounds, the most widely studied in a large series of congeners and derivatives, which have been employed extensively in the treatment of human schistosomiasis, have attracted modest interest in experimental cancer chemotherapy, and have become useful probes in the examination of some aspects of molecular biology.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Adamson, R.H.: Antileukaemic activity of hycanthone. Lancet 1971-II, 1206.
Adamson, R.H.: Hydroxyguanidine and hycanthone—two new antitumor drugs—rationale, evaluation, and activity (Abstract). Proc. Am. Assoc. Cancer Res. 13, 7 (1972).
AMA Council on Drugs: Hycanthone mesylate. In: AMA drug evaluations, 1st edition, 1971, p. 477.
Ames, B.N.: The detection of chemical mutagens with enteric bacteria. In: Chemical mutagens. Principles and methods for their detection, Hollaender, A., ed., p. 267. New York: Plenum Press 1971.
Anonymous: Physical properties of standard reference list of agents. Cancer Res. 23 (4), Pt. 2, 259 (1963).
Archer, S.: Award address. Biological activity: A medicinal chemist’s view. In: Annual report in medicinal chemistry—1967, Cain, C.K., ed., p. VII. New York: Academic Press 1968.
Archer, S., and C.M. Suter: The preparation of some 1-alkylamino- and dialkylamino-thiaxan-thenones. J. Am. Chem. Soc. 74, 4296 (1952).
Aslamazov, E.G., and A.A. Mikhailov: [Toxic effect of trivalent antimony and miracil D preparations on cardiovascular system during therapy of schistosomiasis patients]. Soviet Med. 27, 65 (1963).
Bases, R.: Enhancement of x-ray damage in HeLa cells by exposure to lucanthone (miracil D) following radiation. Cancer Res. 30, 2007 (1970).
Bases, R.: Combined lethal effects of lucanthone (miracil D) and total-body irradiation in mice. Radiology 102, 193 (1972).
Bases, R., and F. Mendez: Reversible inhibition of ribosomal RNA synthesis in HeLa by lucanthone (miracil D) with continued synthesis of DNA-like RNA. J. Cell Physiol. 74, 283 (1969).
Bases, R., F. Mendez, and R. Nicolino: Inhibition of ribosomal RNA synthesis in x-irradiated HeLa cells. Radiation Res. 44, 456 (1970).
Berberian, D.A., H. Freele, D. Rosi, E.W. Dennis, and S. Archer: A comparison of oral and parenteral activity of hycanthone and lucanthone in experimental infections with Schistosoma mansoni. Am. J. Trop. Med. Hyg. 16, 487 (1967a).
Berberian, D.A., H. Freele, D. Rosi, E.W. Dennis, and S. Archer: Schistosomicidal activity of lucanthone hydrochloride, hycanthone and their metabolites in mice and hamsters. J. Parasitol. 53, 306 (1967 b).
Blair, D.M.: Lucanthone hydrochloride. A review. Bull. World Health Organ. 18, 989 (1958).
Blanz, E.J., Jr., and F.A. French: A systematic investigation of thiaxanthen-9-ones and analogs as potential antitumor agents. J. Med. Pharm. Chem. 6, 185 (1963).
Bond, H.W.: Chemistry of schistosomicides. Ann. N.Y. Acad. Sci. 160, 519 (1969).
Brambilla, G., L. Baldini e G. Galli: Osservazioni sull’attività di diversi chemioterapici antineoplastici sullo sviluppo di culture di cellule HeLa e KB. Boll. Soc. Ital. Biol. Sper. 42, 1679 (1966).
Brindle, S.D., E. Hirschberg, and P.R. Gross: Uptake of miracil D by cells of sensitive and miracil D-resistant lines of mouse leukemia L1210. Cancer Res. 24, 1738 (1964).
Bross, I.D.J., and G.S. Tarnowski: A new approach to differential toxicity. Cancer Res. 22 (1), Pt. 2, 46(1962).
Bueding, E.: Metabolism of parasitic helminths. Physiol. Rev. 29, 195 (1949).
Bueding, E.: Mechanisms of action of schistosomicidal agents. J. Pharm. Pharmacol. 11, 385 (1959).
Bueding, E., A. Higashi, L. Peters, and A.D. Valk: Some observations on the action of miracil (l-[β-diethyl-aminoethylamino]-4-methylthioxanthone hydrochloride) against Schistosoma mansoni (Abstract). Federation Proc. 6, 313 (1947).
Burchenal, J.H., V.C. Gregg, J.R. Purple, and W. Kreis: The use of mouse leukemias in the screening of drugs. Proc. 3rd Internat. Congress Chemother., Stuttgart, 1963, p. 932.
Carchman, R. A., E. Hirschberg, and I.B. Weinstein: Miracil D: Effect on the viscosity of DNA. Biochim. Biophys. Acta 179, 158 (1969).
Clive, D., W.G. Flamm, and M.R. Machesko: Mutagenicity of hycanthone in mammalian cells. Mutation Res. 14, 262 (1972a).
Clive, D., W.G. Flamm, M.R. Machesko, and N.J. Bernheim: A mutational assay system using the thymidine kinase locus in mouse lymphoma cells. Mutation Res. 16, 77 (1972b).
Cook, J.A., and P. Jordan: Clinical trial of hycanthone in schistosomiasis mansoni in St.Lucia. Am. J. Trop. Med. Hyg. 20, 84 (1971).
Cramer, J.H., and R.L. Sinsheimer: Replication of bacteriophage MS2. X. Phage-specific ribonucleo-protein particles found in MS2-infected Escherichia coli. J. Mol. Biol. 62, 189 (1971).
Cramer, J.H., and R.L. Sinsheimer: Use of miracil D to suppress bacterial ribonucleic acid and protein synthesis during bacteriophage MS2 infection. J. Virol. 9, 189 (1972).
Da Cunha, A.S., D.G. De Carvalho, J.N. Santos Cambraia y J.R. Cancado: Manifestacoes de intolerancia ao hycanthone no tratamento da esquistossomose mansoni. Rev. Inst. Med. Trop. Sao Paulo 13, 213 (1971).
D’Angio, G.J.: Clinical and biologic studies of actinomycin D and roentgen irradiation. Am. J. Roentgenol. 87, 106 (1962).
Da Silva, L.C., M.E. Camargo, S. Hoshino, J. Gunji, J.D. Lopes, D.F. Chamone, J.O. Martinez, R.G. Ferri, W. Rothstein, G.R. Da Silva, A.C. Ceneviva, and E.J. Cardoso: [Serum antibody and eosinophil changes after treatment of human Manson’s schistosomiasis with niridazole or hycanthone]. Rev. Inst. Med. Trop. Sao Paulo 13, 121 (1971).
Davis, A.: Lucanthone resinates in schistosomiasis. Lancet 1961-I, 201.
Davis, A., J. Newsome, J.R. Henderson, J. Kettle, and L.F. Wiggins: Resinates of lucanthone in the treatment of schistosomiasis. E. African Med. J. 42, 10 (1965); Chem. Abstr. 63, 1104c (1965).
Davis, A.P., M. Gruenstein, and M.B. Shimkin: Evaluation of chemotherapeutic agents in mammary carcinoma induced by 3-methylcholanthrene in Wistar rats. Cancer Res. 26 (2), Pt. 2, 1 (1966).
Einhorn, A., A. Fritsch, K.G. Dwork, and H.B. Shookhoff: Schistosoma mansoni infection in children. Treatment with lucanthone hydrochloride (Nilodin). Am. J. Diseases Children 104, 30 (1962).
El-Sewedy, S.M., G.A. Abdel-Tawab, M.H. Abdel-Daim, and M.F. El-Sawy: Studies with tryptophan metabolites in vitro. V. Effect of the methanesulphonate derivative of hycanthone (etrenol) and lead acetate on kynureninase and kynurenine transaminase of normal mouse liver. Biochem. Pharmacol. 21, 379 (1972).
Elslager, E.F.: Human antiparasitic agents. In: Annual report in medicinal chemistry—1965, Cain, C.K., ed., p. 136. New York: Academic Press 1966.
Elslager, E.F.: Human antiparasitic agents. In: Annual report in medicinal chemistry—1966, Cain, C.K., ed., p. 131. New York: Academic Press 1967.
Elslager, E.F., J.F. Ca valla, W.D. Closson, and D.F. Worth: Synthetic schistosomicides. II. l-[(Dialkylaminoalkyl)-methylamino]-4-methyl-10-thiaxanthenones. J. Org. Chem. 26, 2837 (1961).
Farid, Z., J.H. Smith, S. Bassily, and H.A. Sparks: Hepatotoxicity after treatment of schistosomiasis with hycanthone. Brit. Med. J. 1972, 88.
Foster, R., B.L. Cheetham, E.T. Mesmer, and D.F. King: Comparative studies of the action of mirasan, lucanthone, hycanthone, and niridazole against Schistosoma mansoni in mice. Ann. Trop. Med. Parasitol. 65, 45 (1971).
Foster, R., and H.C. Richards: Recent advances toward the chemotherapeutic control of schistosomiasis. Bull. Chim. Therap. 4, 293 (1970).
Freeman, G., A. Kuehn, and I. Sultanian: Response of tumorigenic viruses and of cells to biologically active compounds. I. Methods for determining response and application of methods. Cancer Res. 25 (10), Pt. 2, 1609 (1965a).
Freeman, G., A. Kuehn, and I. Sultanian: Tumorigenic virus and cell responses to biologically active compounds. II. Pharmacologic specificity in cell-virus relationships. Ann. N.Y. Acad. Sci. 130, 330 (1965 b).
Gane, N.F.C.: Hycanthone: Contraindications to its use. Central African J. Med. 17, 108 (1971).
Garattini, S., and V. Palma: An attempt to evaluate specific effects of antitumoral drugs. Cancer Chemotherapy Rept. 13, 9 (1961).
Gause, G.F., G.V. Kochetkova, and G.B. Vladimirova: Biochemical changes accompanying impaired respiration in staphylocci. Nature 190, 978 (1961).
Gelfand, M.: Temporary mental confusion in the African. Central African J. Med. 10, 125 (1964).
Germiniani, H., F.S. De Lacerda Jr., M.C. Baranski, H.G. Medina, M. Bacila, and C.C. Mota: [Electrocardiographic changes in schistosomiasis patients submitting to treatment with a thiaxanthone derivative]. Rev. Inst. Med. Trop. Sao Paulo 6, 123 (1964).
Gillet, J., R. M. De Smet et P. Nannan: L’action thérapeutique favorable d’un dérivé du thioxanthone (Nilodin) dans la strongyloidose. Ann. Soc. Belge Méd. Trop. 35, 499 (1955).
Goennert, R.: Zur Frage des Wirkungsmechanismus von Miracil. Naturwissenschaften 34, 347 (1947).
Goennert, R.: Schistosomiasis-Studien. III. Über die Einwirkungen von Miracil D auf Schistosoma mansoni im Mäuseversuch und die Verteilung des Pigmentes in der Wirtsleber. Z. Tropenmed. Parasitol. 6, 257 (1955).
Goennert, R.: The structure-activity relationship in several schistosomicidal compounds. Bull. World Health Organ. 25, 702 (1961).
Goennert, R., and H. Koelling: Thiaxanthones and related compounds in experimental schistosomiasis. In: Drugs, parasites, and hosts, Goodwin, L.G., and R.H. Nimmo-Smith, eds., p. 29. London: J. & A. Churchill, Ltd. 1962.
Goodman, L.S., and A. Gilman: Lucanthone. In: The pharmacological basis of therapeutics, 4th ed., p. 1073. New York: MacMillan Co. 1970.
Green, S., F.M. Sauro, and M.S. Legator: Cytogenetic effects of hycanthone in the rat. Mutation Res. 17, 239 (1973).
Griswold, D.P., W.R. Laster, Jr., M.Y. Snow, F.M. Schabel, Jr., and H.E. Skipper: Experimental evaluation of potential anticancer agents. XII. Quantitative drug response of SA 180, CA 755, and leukemia L1210 systems to a “standard list” of “active” and “inactive agents”. Cancer Res. 23 (4), Pt. 2, 271 (1963).
Gropper, L., and M.B. Shimkin: Combination therapy of 3-methylcholanthrene-induced mammary carcinoma in rats: Effect of chemotherapy, ovariectomy, and food restriction. Cancer Res. 27, 26 (1967).
Hackmann, C., R. Goennert u. H. Mauss: Untersuchung über die tumorhemmende Wirkung des Miracils. Naturwissenschaften 36, 29 (1949).
Haese, W.H., D.L. Smith, and E. Bueding.: Hycanthone-induced hepatic changes in mice infected with Schistosoma mansoni J. Pharmacol. Exptl. Therap. 186, 430 (1973).
Haidle, C.W., B.R. Brinkley, and M. Mandel: Effect of miracil D on marker frequency ratio and cytotoxicity in Bacillus subtilis. J. Bacteriol. 102, 835 (1970).
Haidle, C., M.J. Tevethia, and M. Mandel: Effect of miracil D on chromosome completion in Bacillus subtilis (Abstract). Bacteriol. Proc. 1967, 57.
Halawani, A., A. Hafez, J. Newsome, and S.G. Cowper: Miracil D: Effect on B. mansoni in vitro and in the treatment of urinary bilharziasis. J. Egypt. Med. Assoc. 32, 29 (1949).
Hammick, D.L., and D.C. Munro: New synthesis of 1-amino-4-methylthioxanthone and of miracil D. J. Chem. Soc. 1952, 1077.
Harris, J.J.: The effect of NSC survey compounds on human tumors in embryonated eggs. Cancer Res. 22(1), Pt. 2, 1 (1962).
Hartman, P.E., K. Levine, Z. Hartman, and H. Berger: Hycanthone: A frameshift mutagen. Science 172, 1058 (1971).
Hawking, F., and W.F. Ross: Miracil D, its toxicology, absorption, and excretion in animals and human volunteers. Brit. J. Pharmacol. Chemother. 3, 167 (1948).
Hebborn, P., T.J. Bardos, Z.F. Chmielewicz, and D.J. Triggle: Miracil D analogs: DNA-dependent RNA polymerase inhibitory activity and in vivo biological activity (Abstract). Proc. Am. Assoc. Cancer Res. 9, 29 (1968).
Hernandez, P., E.W. Dennis, and A. Farah: Metabolism of the schistosomicidal agent hycanthone by rats and rhesus monkeys. Bull. World Health Organ. 45, 27 (1971).
Hetrick, F.M., and W.L. Kos: Transformation of Rauscher virus-infected cell cultures after treatment with hycanthone and lucanthone. J. Pharmacol. Exptl. Therap. 186, 425 (1973).
Hirschberg, E.: Tissue culture in cancer chemotherapy screening. Cancer Res. 18, 869 (1958).
Hirschberg, E.: Patterns of response of animal tumors to anticancer agents. Cancer Res. 23 (5), Pt. 2, 521 (1963).
Hirschberg, E., S.D. Brindle, and G. Semente: Development and properties of mouse leukemia L1210 resistant to miracil D. Cancer Res. 24, 1733 (1964).
Hirschberg, E., C. Ceccarini, M. Osnos, and R. Carchman: Effects of inhibitors of nucleic acid and protein synthesis on growth and aggregation of the cellular slime mold Dictyostelium discoideum. Proc. Natl. Acad. Sci. U.S. 61, 316 (1968a).
Hirschberg, E., A. Gellhorn, M.R. Murray, and E.F. Elslager: Effects of miracil D, amodiaquin, and a series of other 10-thiaxanthenones and 4-aminoquinolines against a variety of experimental tumors in vitro and in vivo. J. Natl. Cancer Inst. 22, 567 (1959).
Hirschberg, E., and I.B. Weinstein: Comparative ability of hycanthone and miracil D to interact with DNA. Science 174, 1147 (1971).
Hirschberg, E., I.B. Weinstein, and R. Carchman: Miracil D: An inhibitor of deoxyribonucleic and ribonucleic acid synthesis in mouse leukemia L1210 ascites (Abstract). Abstr. 9th Internat. Cancer Congress, Tokyo, 1966, p. 347.
Hirschberg, E., I.B. Weinstein, R. Carchman, and S. Archer: Search for the carcinostatic metabolite of miracil D (Abstract). Proc. Am. Assoc. Cancer Res. 9, 30 (1968 b).
Hirschberg, E., I.B. Weinstein, N. Gersten, E. Marner, T. Finkelstein, and R. Carchman: Structure-activity studies on the mechanism of action of miracil D. Cancer Res. 28, 601 (1968 c).
Hoffer, M., and A.I. Rachlin: Antiparasitic agents. In: Annual report in medicinal chemistry, Heinzelman, R.V., ed., vol. 7, p. 145. New York: Academic Press 1972.
Hussein, A.M., A.A. Kassem, A. Sina, and A.A. Badawy: Factors affecting exchange rate of lucanthone by amberlite IR-120 resin. I. Effect of solvent. Bull. Fac. Pharm. Cairo Univ. 7, 73 (1968a); Chem. Abstr. 73, No. 38493h (1970).
Hussein, A.M., A.A. Kassem, A. Sina, and A.A. Badawy: Factors affecting exchange rate of lucanthone by amberlite IR-120. II. Effect of concentration and solution volume. Bull. Fac. Pharm. Cairo Univ. 7, 81 (1968b); Chem. Abstr. 73, No. 38492g (1970).
Hutchison, D.J., D.L. Robinson, D. Martin, O.L. Ittensohn, and J. Dillenberg: Effects of selected cancer chemotherapeutic drugs on the survival times of mice with L-1210 leukemia: Relative responses of antimetabolite resistant strains. Cancer Res. 22 (1), Pt. 2, 57 (1962a).
Hutchison, D.J., W.V. Zucker, and E.A. Brand: Effects of selected cancer chemotherapeutic drugs on the growth of Streptococcus faecalis: Relative responses of antimetabolite resistant strains. Cancer Res. 22 (1), Pt. 2, 73 (1962b).
Jacquez, J.A.: Tissue culture screening. Cancer Res. 22 (1), Pt. 2, 81 (1962).
Jewsbury, J.M.: Experimental chemoprophylaxis against schistosomiasis. I. Introduction and rationale. Ann. Trop. Med. Parasitol. 66, 409 (1972).
Jordan, P., and G. Webbe: Human schistosomiasis. London: William Heinemann Medical Books, Ltd. 1969.
Karnofsky, D.A., and C.R. Lacon: Survey of cancer chemotherapy service center compounds for teratogenic effect in the chick embryo. Cancer Res. 22 (1), Pt. 2, 84 (1962).
Katz, N., J. Pellegrino, M.T. Ferreira, C.A. Oliveira, and C.B. Dias: Preliminary clinical trials with hycanthone, a new antischistosomal agent. Am. J. Trop. Med. Hyg. 17, 743 (1968).
Katz, N., J. Pellegrino, and C.A. Ouveira: Further clinical trials with hycanthone, a new antischistosomal agent. Am. J. Trop. Med. Hyg. 18, 924 (1969).
Kikuth, W., and R. Goennert: Experimental studies on the therapy of schistosomiasis. Ann. Trop. Med. Parasitol. 42, 256 (1948).
Kikuth, W. u. R. Goennert: Experimentelle Untersuchungen und Erfahrungen mit dem neuen Schistosomiasismittel Miracil. Z. Tropenmed. Parasitol. 1, 234 (1949).
Kikuth, W., R. Goennert u. H. Mauss: Miracil, ein neues Chemotherapeuticum gegen Darmbilharziose. Naturwissenschaften 33, 253 (1946); Chem. Abstr. 43, 9251 i (1949).
Kuhnert-Brandstaetter, M., A. Kofler u. H.C. Rhi: Beitrag zur mikroskopischen Charakterisierung und Identifizierung von Arzneimitteln. Sci. Pharm. 32, 308 (1964).
Kux, P.: Die Wirkung von Miracil D bei Asthma bronchiale. Medizinische 5, 230 (1956).
Laemmler, G.: Chemotherapeutic activity of drugs in experimental schistosomiasis and other trematode-infections. Ann. Soc. Belge Méd. Trop. 47, 215 (1967).
Laemmler, G.: Chemotherapy of trematode infections. In: Advances in chemotherapy, Goldin, A., F. Hawking, and R.J. Schnitzer, eds., vol. 3, p. 153. New York: Academic Press 1968.
Lang, K., G. Siebert u. W. Loennecke: Über biochemische Wirkungen von Miracil D. Klin. Wochschr. 28, 104(1950).
Latner, A.L., R.V. Coxon, and E.J. King: Measurement of the concentration of miracil in biological fluids. Trans. Roy. Soc. Trop. Med. Hyg. 41, 133 (1947).
Lea, M.A., F.L. Khalil, and M.I. Rey: Inhibition of histone synthesis and phosphorylation of lysine-rich histones in regenerating liver by miracil D and hycanthone (Abstract). Federation Proc. 32, 588 Abs (1973).
Lea, M.A., S. Miller, I. Mackauf, E. Hirschberg, and H.P. Morris: Action of miracil D and related compounds on DNA and RNA synthesis in regenerating liver and hepatomas. Internat. J. Cancer 9, 484(1972).
Lee, H.G.: Aspects of the effect of thioxanthone on Schistosoma mansoni in mice and in vitro. Bull. World Health Organ. 46, 397 (1972).
Leiter, J.: Cancer chemotherapy screening data. XIII. Cancer Res. 22 (1), Pt. 2, 1 (1962).
Lerman, L.S.: Structural considerations in the interaction of DNA and acridines. J. Mol. Biol. 3, 18(1961).
Lubinsky, G.: Attempts at chemotherapy of Echinococcus multilocularis infections in rodents. Can. J. Zool. 47, 1001 (1969); Chem. Abstr. 71, No. 100154n (1969).
Lüers, H.: Biologisch-genetische Untersuchungen über die Wirkung eines Thioxanthonderivates an Drosophila melanogaster. Z. Induktive Abstammungs-Vererbungslehre 87, 93 (1955).
Mandel, M., and B.R. Brinkley: Effect of miracil D on the ultrastructure of Bacillus subtilis and other bacteria (Abstract). Bacteriol. Proc. 1967, 57.
Mauss, H.: Über basisch substituierte Xanthon- und Thioxanthon-Abkömmlinge; Miracil, ein neues Chemotherapeuticum. Chem. Ber. 81, 19 (1948).
Merker, P.C., P. Anido, J. Sarino, and G.W. Woolley: A study of human epidermoid carcinoma (H. Ep. No. 3) growing in conditioned Swiss mice. III. Chemotherapy with selected chemicals and observations on diet, food intake and drug toxicities. Cancer Res. 22 (1), Pt. 2, 9 (1962).
Moore, J.A.: Teratogenicity of hycanthone in mice. Nature 239, 107 (1972).
Moran, M.R., and G.W. Woolley: Chemotherapy of a transplantable mammary tumor in strain C3H mice. Cancer Res. 22 (1), Pt. 2, 87 (1962).
Morasca, L.: Duration of cytoxicity in blood after treatment with antitumoral agents. In: Fifth International Congress of chemotherapy. Proceedings, Spitzy, K.H., ed., vol. 3, p. 383; Chem. Abstr. 70, No. 18563r (1969). Vienna: Verlag Wien. Med. Akad. 1967.
Morasca, L., and C. Rainisio: A method to perfuse tissue culture with an in vivo system: Reliability of the method for metabolic studies. In: Cancer chemotherapy. Proceeding of Takeda International Conference, Osaka 1966, Goldin, A., ed., p. 141 ; Chem. Abstr. 70, No. 36187a (1969). Tokyo: Maruzen Co., Ltd. 1967.
Most, H.: Drug therapy. Treatment of common parasitic infections of man encountered in the United States. New Engl. J. Med. 287, 495 and 698 (1972).
Munro, D.C.: Polarography of 1-amino-4-methylthioxanthone and of miracil D. J. Chem. Soc. 1960, 4579.
Munro, D.C.: Physicochemical properties of some chemotherapeutic thioxanthones. J. Chem. Soc. 1961, 5381.
Nabih, I., and M. Elsheikh: Chlorination and condensation reactions at the 4-methyl group of lucanthone and oxalucanthone. J. Pharm. Sci. 54, 1672 (1965a).
Nabih, I., and M. Elsheikh: Mannich reaction at the 4-methyl group in schistosomicidal agents, lucanthone and oxalucanthone. J. Pharm. Sci. 54, 1821 (1965b).
Newsome,. J.: The search for non-antimonial schistosomicides. In: Bilharziasis, Wolstenholme, G.E.W., and M. O’Connor, eds., Ciba Foundation Symposium, p. 310. Boston: Little, Brown & Co. 1962.
Newsome, J., and D.L.H. Robinson: Preliminary observations on metabolites of lucanthone. Trans. Roy. Soc. Trop. Med. Hyg. 54, 582 (1960a).
Newsome, J., and D.L.H. Robinson: The estimation of lucanthone in plasma and serum. Trans. Roy. Soc. Trop. Med. Hyg. 54, 454 (1960b).
Newton, B.A.: Chemotherapeutic compounds affecting DNA structure and function. In: Advances in pharmacology and chemotherapy, Garattini, S., F. Hawking, A. Goldin, and I.J. Kopin, eds., vol. 8, p. 149. New York: Academic Press 1970.
Nor El Din, G., and M. Dawood: Observations on the side-effects of miracil D. J. Egypt. Med. Assoc. 33, 688 (1950).
Obe, G.: Zur Wirkung von Miracil auf menschliche Leukozytenchromosomen in vitro. Mol. Gen. Genet. 103, 326 (1969).
Obe, G.: Die Verteilung Miracil D-induzierter achromatischer Läsionen und Chromatidbrüche auf den Chromosomen menschlicher Leukozyten. Z. Naturforsch. 25b, 115 (1970).
Pellegrino, J., and N. Katz: Experimental chemotherapy of schistosomiasis mansoni. In: Advances in parasitology, Dawes, B., ed., vol. 6, p. 233. New York: Academic Press 1968.
Pellegrino, J., and N. Katz: Laboratory evaluation of antischistosomal agents. Ann. N.Y. Acad. Sci. 160, 429(1969).
Pirwitz, J., B. Schwaer u. K.A. Seyfarth: Das Ehrlich-Asziteskarzinom der Maus als Testobjekt zytostatischer Substanzen: Lost, Urethan, Colchicin, Folinsäure, Miracil. Mikroskopie (Vienna), Sonderbd. 3, 29(1949).
Prescott, B.: Some new salts of lucanthone as potential anticancer agents. J. Med. Pharm. Chem. 11, 156 (1968).
Rey, M.: Studies on the inhibition of DNA and histone synthesis in regenerating liver and hepatomas. M.S. Thesis, Graduate School of Biomedical Sciences, College of Medicine and Dentistry of New Jersey, Newark, New Jersey, 1973.
Rogers, S.H., and E. Bueding: The effects of hycanthone on Schistosoma mansoni in mice and hamsters (Abstract). Proc. 2nd Internat. Congress Parasitol. J. Parasitol. 56, 288 (1970).
Rogers, S. H., and E. Bueding: Hycanthone resistance: Development in Schistosoma mansoni. Science 172, 1057 (1971).
Rosi, D., G. Peruzzotti, E.W. Dennis, D.A. Berberian, H. Freele, and S. Archer: A new, active metabolite of miracil D. Nature 208, 1005 (1965).
Rosi, D., G. Peruzzotti, E.W. Dennis, D.A. Berberian, H. Freele, B.F. Tullar, and S. Archer: Hycanthone, a new active metabolite of lucanthone. J. Med. Pharm. Chem. 10, 867 (1967).
Salgado, J.A., C. Veloso, C.A. Oliveira, D.A.F. Chamone, M.S. Lemos, N. Katz y J. Pellegrino: Alteracoes electrocardiograficas observadas em pacientes com esquistossomose mansoni tratadoscom um derivado hidroximetilico do Miracil D (Hycanthone). Rev. Inst. Med. Trop. Sao Paulo 10, 312 (1968).
Sallam, L.A.R., A. El-Refai, and H.A. Shoeb: Microbiological transformation of lucanthone. Indian J. Exptl. Biol. 9, 276 (1971).
Scholtan, W.: Kolloidchemische Eigenschaften von Salzen basisch substituierter Xanthon- und Thioxanthonderivate. Kolloid-Z. 170, 19 (1960).
Scholtan, W., and R. Goennert: The relation between weight of micelles and the biological activity of xanthones and thioxanthones effective against bilharziasis. Med. Chem. Abhandl. Med.-Chem. Forschungsstätten Farbenfabriken Bayer 5, 314 (1956); Chem. Abstr. 55, 8766e (1961).
Sen, A.B., and F. Hawking: The action of drugs in vitro on tapeworm (Hymenolepsis nana). Ann. Biochem. Exptl. Med. (Calcutta) 20, Suppl., 547 (1960).
Senft, A. W.: Recent developments in the understanding of amino-acid and protein metabolism by Schistosoma mansoni in vitro. Ann. Trop. Med. Parasitol. 59, 164 (1965).
Senft, A.W.: Considerations of schistosome physiology in the search for antibilharziasis drugs. Ann. N.Y. Acad. Sci. 160, 571 (1969).
Sharp, T.M.: New synthesis of lucanthone (miracil D, nilodin). J. Chem. Soc. 1951, 2961.
Sieber, S.M., J. Whang-Peng, D.G. Johns, and R.H. Adamson: Effects of hycanthone on rapidly proliferating cells. Biochem. Pharmacol. 22, 1253 (1973).
Sobell, S.D., and A. Arnold: Inhibition studies with Streptococcus faecalis. Xanthones and thiaxanthones. Proc. Soc. Exptl. Biol. Med. 90, 594 (1955).
Standen; O.D.: Chemotherapy of helminthic infections. In: Experimental chemotherapy, Schnitzer, R.J., and F. Hawking, eds., vol. 1, p. 701. New York: Academic Press 1963.
Strufe, R.: Stoffwechsel-Untersuchungen mit Miracil D. Med. Chem. Abhandl. Med.-Chem. Forschungsstätten Farbenfabriken Bayer 7, 337 (1963).
Sugiura, K.: Studies in a spectrum of mouse, rat and hamster tumors. Cancer Res. 22 (1), Pt. 2, 93 (1962).
Sugiura, K., F.A. Schmid, G.F. Brown, and R. Gonzáles: Chemotherapy of hamster tumors. Cancer Chemother. Rept. 2 (1), Pt. 2, 141 (1971).
Sugiura, K., F.A. Schmid, M.M. Schmid, and G.F. Brown: Effects of compounds on a spectrum of rat tumors. Cancer Chemother. Rept. 3 (1), Pt. 2, 231 (1972).
Surrey, A.R., and A. Yarinsky: Human antiparasitic agents. In: Annual report in medicinal chemistry—1967, Cain, C.K., ed., p. 126. New York: Academic Press 1968.
Surrey, A.R., and A. Yarinsky: Human antiparasitic agents. In: Annual report in medicinal chemistry—1968, Cain, C.K., ed., p. 126. New York: Academic Press 1969.
Tarnowski, G.S., and I.D.J. Bross: Titration of the effects of a group of selected chemicals on the growth of ascites and solid forms of the Nelson mouse tumor. Cancer Res. 22 (1), Pt. 2, 136 (1962).
Teller, M.N.: Chemotherapy of transplantable human tumors in the rat. Cancer Res. 22 (1), Pt. 2, 25 (1962).
Thayer, P.S., P. Himmelfarb, and G.L. Watts: Cytotoxicity assays with L1210 cells in vitro: Comparison with LI210 in vivo and KB cells in vitro. Cancer Chemother. Rept. 2 (1), Pt. 2, 1 (1971).
Thorp, J.M., E.W. Hurst, and A.R. Martin: The effect of β-diethylaminoethyl diphenylpropylacetate hydrochloride (SKF 525-A) on the therapeutic action of a variety of antibacterial, antiviral, or antiprotozoal drugs. J. Med. Pharm. Chem. 2, 15 (1960). U, R.: Enhancing effect of lucanthone (miracil D) on the frequency of x-ray-induced chromosomeloss in Drosophila male germ cells. Mutation Res. 14, 315 (1972).
U. R.: Enhancing effect of lucanthone (miracil D) on the frequency of x-ray-induced chromosomeloss in Drosophila male germ cells. Mutation Res. 14, 315 (1972).
Vargas, M.: Carcinoma del endometrio. Tratamiento. Rev. Obstet. Ginecol. (Caracas) 23, 385 (1963).
Waring, M.J.: Drugs and DNA: Uncoiling of the DNA double helix as evidence of intercalation. Humangenetik 9, 234 (1970).
Waring, M.: Variation of the supercoils in closed circular DNA by binding of antibiotics and drugs: Evidence for molecular models involving intercalation. J. Mol. Biol. 54, 247 (1970).
Waring: M.: Binding of drugs to supercoiled circular DNA: Evidence for and against intercalation. In: Progress in molecular and subcellular biology, Hahn, F.E., ed., vol. 2, p. 216. Berlin-Heidelberg-New York: Springer 1971.
Waring, M.J.: Inhibitors of nucleic acid synthesis. In: The molecular basis of antibiotic action, Gale, E.F., E. Cundliffe, P.E. Reynolds, M.H. Richmond, and M.J. Waring, eds., p. 173. London: Wiley 1972.
Waring, M.J.: Interaction of indazole analogs of lucanthone and hycanthone with closed circular duplex deoxyribonucleic acid. J. Pharmacol. Exptl. Therap. 186, 385 (1973).
Warren, K.S.: Treatment of molluscan schistosomiasis mansoni with antibiotics, nonantibiotic metabolic inhibitors, molluscicides, and antischistosomal agents. Trans. Roy. Soc. Trop. Med. Hyg. 61, 368 (1967); Chem. Abstr. 67, No. 51541 t (1967).
Weinstein, I.B., R. Carchman, E. Marner, and E. Hirschberg: Miracil D: Effects on nucleic acid synthesis, protein synthesis, and enzyme induction in Escherichia coli. Biochim. Biophys. Acta 142, 440(1967).
Weinstein, I.B., R. Chernoff, I. Finkelstein, and E. Hirschberg: Miracil D: An inhibitor of ribonucleic acid synthesis in Bacillus subtilis. Mol. Pharmacol. 1, 297 (1965).
Weinstein, I.B., and E. Hirschberg: Mode of action of miracil D. In: Progress in molecular and subcellular biology, Hahn, F.E., ed., vol. 2, p. 232. Berlin-Heidelberg-New York: Springer 1971.
Weyland, H.: Untersuchungen über die Beeinflussung der Pflanze durch chemische Substanzen und ihre Bedeutung für die Beurteilung gewisser medizinischer Fragen. Z. Krebsforsch. 56, 148 (1948).
Weyland, H., R. Weyland, K.W. Cremer, J. Reinert u. H.U. Koecke: Die Beeinflussung der Pflanze durch chemische Substanzen. Biol. Zentralblatt 68, 140 (1949).
Willard, F.L., and R. Kodras: Survey of chemical compounds tested in vitro against rumen protozoa for possible control of bloat. Appl. Microbiol. 15, 1014 (1967).
Wilson, R., J. Church, R. Bodner, N. Sylvain, and E. Hirschberg: The effect of miracil D and analogs upon nucleic acid synthesis in leukemia L1210 cells (Abstract). Proc. Am. Assoc. Cancer Res. 13, 76 (1972a).
Wilson, R.G., J.A. Church, and N.P. Sylvain: The effect of miracil D upon the template properties of polynucleotides for a bacterial RNA polymerase. Biochim. Biophys. Acta 277, 564 (1972b).
Wittner, M., H. Tanowitz, and R.M. Rosenbaum. Studies with the schistosomacide hycanthone: Inhibition of macromolecular synthesis and its reversal. Exptl. Mol. Pathol. 14, 124 (1971).
Wolfe, A.D., R.G. Allison, and F.E. Hahn: Labilizing action of intercalating drugs and dyes on bacterial ribosomes. Biochemistry 11, 1569 (1972).
Wood, D.R.: Observations on the pharmacology of miracil, a new chemotherapeutic agent for schistosomiasis. Quart. J. Pharm. Pharmacol. 20, 31 (1947).
Woolley, G.W.: Chemotherapy of transplantable human tumors in the hamster. Cancer Res. 22 (1), Pt. 2, 34 (1962).
Wright, C.A.: The schistosome life-cycle. In: Bilharziasis, Mostofi, K., ed., p. 3. Berlin-Heidelberg-New York: Springer 1967.
Yarinsky, A., and H. Freele: A comparison of molluscicidal and mollusc inhibitory activity of hycanthone and lucanthone and the effect of the drugs on the development of Schistosoma mansoni in the snail intermediate host, Australobris glabratus. J. Trop. Med. Hyg. 73, 23 (1970).
Yarinsky, A., P. Hernandez, and E.W. Dennis: The uptake of tritiated hycanthone by male and female Schistosoma mansoni worms and distribution of the drug in plasma and whole blood of mice following a single intramuscular injection. Bull. World Health Organ. 42, 445 (1970).
Zilversmit, R.: Thioxanthones. Structural differences between lucanthone and its N-methyl derivative. Mol. Pharmacol. 6, 172 (1970)
Zilversmit, R.: Thioxanthones. II. Studies on the hydrogen-bonding capacity of lucanthone. Mol. Pharmacol. 7, 674(1971).
Zussman, R.A., and P.M. Bauman: Schistosome hemoglobin protease; search for inhibitors. J. Parasitol. 57, 233 (1971).
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1975 Springer-Verlag Berlin Heidelberg
About this chapter
Cite this chapter
Hirschberg, E. (1975). Thiaxanthenones: Miracil D and Hycanthone. In: Corcoran, J.W., Hahn, F.E., Snell, J.F., Arora, K.L. (eds) Mechanism of Action of Antimicrobial and Antitumor Agents. Antibiotics, vol 3. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-46304-4_18
Download citation
DOI: https://doi.org/10.1007/978-3-642-46304-4_18
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-642-46306-8
Online ISBN: 978-3-642-46304-4
eBook Packages: Springer Book Archive